Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) Meeting Abstract

publication date

June 1, 2021

webpage

Web of Science

published in

EUROPEAN UROLOGY Journal

start page

S1180

end page

S1181

volume

79